Pharmacological criteria for a substitutive drug in the treatment of opioid dependence

被引:9
|
作者
Montastruc, JL
Arnaud, P
Barbier, C
Berlin, I
Gatignol, C
Haramburu, F
Lagier, G
Lapeyre-Mestre, M
Mallaret, M
Micaleff, J
机构
[1] Fac Med Toulouse, Serv Pharmacol Clin, F-31073 Toulouse, France
[2] Fac Med Toulouse, Ctr Evaluat & Informat Pharmacodependance, F-31073 Toulouse, France
[3] CHU Rouen, Serv Pharm, Rouen, France
[4] DGS, Bur Prat Addict, Paris, France
[5] CHU Pitie Salpetriere, CEIP, Paris, France
[6] Unite Stupefiants & Psychotropes, St Denis, France
[7] CEIP, Serv Pharmacol Clin, Bordeaux, France
[8] CHU Pitie Salpetriere, CEIP, Serv Pharmacol Clin, Paris, France
[9] CEIP, Serv Pharmacol Clin, Grenoble, France
[10] CEIP, Serv Pharm Clin, Marseille, France
来源
THERAPIE | 2003年 / 58卷 / 02期
关键词
opiate dependance; buprenorphine; methadone; morphine; codeine; pharmacodependance; substance abuse;
D O I
10.2515/therapie:2003017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Our goal was to establish new pharmacological criteria for a drug to be used in the treatment of opioid dependence. We propose the following six pharmacodynamic and pharmacokinetic criteria: (i) the same pharmacodynamic properties as the drug being substituted; (ii) a long duration of action (minimum 24 hours, not requiring several daily doses) in order to prevent fluctuations in effect and especially withdrawal symptoms; (iii) few euphoric effects together with a minimal reinforcing effect for the drug itself and other drugs; (iv) oral or sublingual administration without any special affinity for other routes, especially the intravenous; (v) a New Drug Application (NDA) in this indication, after submission of a dossier including both clinical randomised comparative trials and security data; and (vi) compatibility with a socially satisfying quality of life. These criteria were applied to methadone, buprenorphine and other drugs that were proposed in the treatment of opioid dependence (such as morphine or codeine).
引用
收藏
页码:123 / 125
页数:3
相关论文
共 50 条